GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers: London, UK Tuesday, April 14, 2026, 13:00 Hrs [IST] GSK plc announced positive findings from its globa ...

Proprietary capsid engineering supports comparable cardiac gene delivery at 5–10-fold lower vector doses, potentially improving batch economics, easing purification constraints, and widening ...

Mo-Rez achieved confirmed objective response rates of 62% in patients with platinum-resistant ovarian cancer. Credit: MMD ...

Welcome to the energetic and funny issei Channel!! Please subscribe if you like this videos, and hit the Like button and ...

HONG KONG, April 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a ...

Welcome to the energetic and funny issei Channel!! Please subscribe if you like this videos, and hit the Like button and Share! Stay tuned for more amazing contents! - Smile and Love from Japan - #sho ...

Autolus Therapeutics (NASDAQ:AUTL) hosted an investor event focused on its acute lymphoblastic leukemia (ALL) program, ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Gilead Sciences agreed to acquire Tubulis GmbH for upwards of $5 billion in a deal that significantly expands Gilead's oncology pipeline and establishes Munich as a dedicated antibody-drug conjugates ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...

CNW/ - Health Canada has granted a Notice of Compliance (NOC) for Saphnelo® (anifrolumab injection) for subcutaneous self-administration via a ...

The Japanese pharma is currently investigating mezagitamab’s potential in two late-stage autoimmune programmes.